quinta-feira, 5 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 30, 2026

Chevron (CVX) Q4 2025 Earnings Call Transcript

View original at finance.yahoo.com
Chevron (CVX) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. Date Friday, January 30, 2026 at 11 a.m. ET Call participants Chairman and Chief Executive Officer — Michael K…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Chevron is bigger, stronger, and more resilient than ever

    80% confidence
  • Production growth excluding Hess achieved 6-8% at top end of guidance in 2025

    80% confidence
  • Gulf of America target is 300,000 bbl/day oil equivalent by 2026

    80% confidence
  • Tengiz expected to grow 30,000 bbl/day in 2026

    80% confidence
  • Chemical surfactant treatments show 20% improvement in 10-month cumulative recovery and 10% uplift over well life

    80% confidence
  • Venezuela operations have potential for up to 50% production growth over next 18-24 months pending US authorizations

    80% confidence
  • Permian Basin achieved 1 million bbl/day oil equivalent and will maintain plateau at 1 million+ bbl/day in 2026

    80% confidence
  • Reserve replacement ratio leads peer group on 5-year and 10-year basis

    80% confidence
  • 2026 production guidance is 7-10% increase year-over-year excluding asset sales

    80% confidence
  • Dividend and CapEx breakeven is below $50 Brent

    80% confidence
  • US refinery throughput achieved highest level in 20 years

    80% confidence
  • 2026 cost reduction target is $3-4 billion expanded from original target

    80% confidence
  • Venezuela refining sends 50,000 bbl/day to Pascagoula with capacity for 100,000+ bbl/day additional to Pascagoula and El Segundo

    80% confidence
  • Tengiz expected to generate $6 billion Chevron-share free cash flow in 2026 at $70 Brent

    80% confidence
  • Existing well treatments in Permian show 5-8% production decline mitigation with 300 treatments completed

    80% confidence
  • Total shareholder returns 2022-2025 exceeded $100 billion in dividends and buybacks

    80% confidence
  • 2025 was highest full-year worldwide and US production in company history

    80% confidence
  • Bakken reduced rigs from 4 to 3 with similar output

    80% confidence
  • Adjusted free cash flow was $20 billion for 2025, up 35% year-over-year excluding asset sales despite oil prices down 15%

    80% confidence
  • Drilling efficiency in Permian doubled since 2022

    80% confidence
  • Eastern Mediterranean combined projects will deliver 25% production increase and doubling of earnings and free cash flow by 2030

    80% confidence
  • Eastern Mediterranean gross resource is 40+ TCF across core assets

    80% confidence
  • Tamar increasing to 1.6 BCF/day, adding approximately 500 million CF/day

    80% confidence
  • Leviathan currently adding 200 million CF/day near-term with expansion to 2.1 BCF/day by end of decade

    80% confidence
  • Venezuela production increased 200,000+ bbl/day since 2022 with current gross production of approximately 250,000 bbl/day

    80% confidence
  • 60%+ of cost savings come from durable efficiency gains

    80% confidence
  • We've been a pivotal part of Venezuela's past. We're committed to the present, and we look forward to a continued partnership into the future

    80% confidence
  • Bakken target is approximately 200,000 bbl/day plateau with 60% long lateral wells in 2026 and 90% by 2027

    80% confidence
  • 85% of new Permian wells will use chemical surfactant treatments in 2026, targeting 100% by 2027

    80% confidence
  • 2025 cost reduction achieved $1.5 billion saved with $2 billion+ annual run rate

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,549 documentos-fonte arquivados
Consulte estes dados → isubstrate.com